Previous Article | Next Article 
Journal of Clinical Microbiology, May 1998, p. 1422-1424, Vol. 36, No. 5
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Recurrent Catheter-Related Infection Caused by a
Single Clone of Mycobacterium chelonae with Two
Colonial Morphotypes
Po-ren
Hsueh,1,2
Lee-jene
Teng,3
Pan-chyr
Yang,2
Yu-chi
Chen,1
Shen-wu
Ho,3 and
Kwen-tay
Luh1,2,*
Departments of
Laboratory
Medicine1 and
Internal
Medicine,2 National Taiwan University Hospital,
and
School of Medical Technology, National Taiwan University
College of Medicine,3 Taipei, Taiwan
Received 30 December 1997/Returned for modification 5 February
1998/Accepted 20 February 1998
 |
ABSTRACT |
We describe herein a recurrent catheter-related (Port-A-Cath;
Smiths Industries Medical Systems [SIMS] Deltec, Inc., St. Paul, Minn.) infection caused by multidrug-resistant Mycobacterium
chelonae with two colonial morphotypes in a 53-year-old woman
with gastric adenocarcinoma. Four isolates recovered from this patient
within a 3-month period were found to belong to a single clone on the basis of the isolates' identical antibiotypes as determined by the E
test and their identical random amplified polymorphic DNA patterns.
 |
TEXT |
Mycobacterium chelonae, a
rapidly growing mycobacterium, is an opportunistic pathogen which
causes a wide variety of clinical syndromes (2, 3, 5, 8, 9, 12,
15, 18). Nosocomial infections associated with the use of various
indwelling devices and diagnostic instruments have been reported
(7, 16, 17). The propensity of the organism to adhere to the
cardiac valve or vessel walls resulting in endocarditis or aortitis has
also been described (3, 5, 9). However, none of the previous reports have described the use of molecular typing methods to document
the long-term persistence of M. chelonae in the catheter and/or the walls of vessels, which contributed the recurrent nature of
intravenous catheter-related infection caused by this organism (18).
Case report.
A 53-year-old woman with gastric adenocarcinoma
underwent subtotal gastrectomy in 1993. She began to receive weekly
intravenous infusions of fluorouracil (2,500 mg) in November 1996. The
first catheter (Port-A-Cath; Smiths Industries Medical Systems [SIMS] Deltec, Inc., St. Paul, Minn.) was implanted via the right subclavian vein on 25 November 1996. She first developed fever and shaking chills
several minutes after each manipulation of the Port-A-Cath device in
June 1997. Two sets of cultures of blood aspirated via the catheter and
cultured in a BACTEC 6A aerobic bottle (Becton Dickinson, Sparks, Md.)
on 7 July 1997 both yielded M. chelonae with a smooth
colonial morphotype (isolate A). The chest roentgenography was
negative. She received lomefloxacin (200 mg every 12 h) for a
total of 14 days, and the catheter was removed on 14 July. A second
Port-A-Cath device was implanted via the left subclavian vein. The
removed catheter was not sent for microbiologic studies. One month
after the second catheter implantation, fever developed and tenderness,
erythema, and pus discharge at the insertion site of the catheter were
noticed. The wound culture was negative for M. chelonae or
other organisms. The catheter was removed on 20 August, and a third
catheter was implanted via the right subclavian vein. During the
following month, the patient felt febrile after each infusion of the
chemotherapy agent via the catheter, although the third catheter
insertion site was absent of any signs of infection. However, the wound
of the second insertion site did not heal satisfactorily and had
persistent pus discharge.
The patient was admitted again on 13 October 1997. A wedge-shaped
consolidation over the lower lobe of the right lung and a nodular patch
over the right midlung field were found by chest roentenography and
sonography. A skin biopsy of the soft tissue from the second insertion
site revealed granulomatous inflammation and numerous acid-fast
bacilli. The third catheter was removed on 15 October. A smear of the
blood from the catheter showed many clusters of acid-fast bacilli.
Culture of the biopsied skin tissue yielded M. chelonae with
a smooth-colony morphotype (isolate B). However, a culture of the
catheter tip and two sets of blood cultures collected immediately after
the removal of the catheter all yielded M. chelonae with two
colonial morphologies, i.e., small and smooth (isolate C) and large and
rough (isolate D). Cultures of sputum, throat and nasal swabs, stool,
urine, and skin were all negative for M. chelonae.
The patient started receiving clarithromycin (500 mg every 12 h),
ciprofloxacin (300 mg every 12 h), and intravenous amikacin (750 mg every day) therapy on 15 October. Acid-fast stain and culture of an
aspirate of the lung lesion, which were performed 7 days after the
start of antibiotic treatment, were both negative for mycobacteria.
Magnetic resonance imaging and magnetic resonance angiography of the
chest revealed a focal stenosis of the right subclavian vein; the left
subclavian, bilateral branchiocephalic, and internal jugular veins and
the superior vena cava were patent. The antibiotics continued for 1 month, followed by clarithromycin and ciprofloxacin for an additional 1 month. A follow-up examination revealed that the lesions of the right
lung and the right subclavian vein had disappeared.
Microbiology.
All isolates (isolates A to D) grew well on the
Trypticase soy agar supplemented with 5% sheep blood agar (BBL
Microbiology Systems, Cockeysville, Md.) and Middlebrook 7H11 agar (BBL
Microbiology Systems) within 3 days of incubation. Two different
colonial morphotypes were observed on both the blood agar plate (Fig.
1) and the Trypticase soy agar. Growth on
MacConkey agar (BBL Microbiology Systems) of these isolates was evident
on the fourth day of incubation. The isolates were differentiated from
Mycobacterium fortuitum and Mycobacterium
abscessus and identified as M. chelonae because they
had all of the following characteristics: failure to grow in 5% NaCl;
positive citrate and arylsulfatase reactions at 3 days; negative
nitrate reduction and mannitol utilization reactions; negative for
alkaline phosphatase, trypsin, and
-glucosidase (API ZYM system;
bioMérieux Vitek, Inc., Hazelwood, Mo.); and resistance to
polymyxin (300-U) and cephalothin (30-µg) disks (BBL Microbiology
Systems) (8, 11, 16).

View larger version (106K):
[in this window]
[in a new window]
|
FIG. 1.
Colonial morphology of M. chelonae grown on
the primary isolation plate (Trypticase soy agar supplemented with 5%
sheep blood) from the Port-A-Cath tip after 3 days of incubation.
Arrow, large, flat, rough, and wrinkled colony (isolate C); arrowhead,
small and smooth colony (isolate D).
|
|
Cellular fatty acid analysis.
The procedure for the extraction
and derivation of methyl esters of mycobacterial lipids was performed
as described previously (4, 11). All isolates had major
cellular fatty acid peaks (
3% of total fatty acid) of 14:0
(tetradecanoic acid), 16:0 (hexadecanoic acid), 18:1 (octadecanoic
acid), 18:0 (octadecanoic acid), and TBSA (tuberculostearic acid) and
minor peaks of 16:1 (hexadecanoic acid), 17:0 (heptadecanoic acid), and
2-OH-20:0 (2-hydroxyeicosanoic acid). The cellular fatty acid profile
was characteristic for the identification of the M. chelonae
group (7).
Antimicrobial susceptibilities.
In vitro susceptibilities of
these isolates, determined by the E test (PDM Epsilometer; AB Biodisk,
Solna, Sweden), were measured on Mueller-Hinton agar supplemented with
5% sheep blood (BBL Microbiology Systems), and the results were read
after 72 h of incubation (6). All isolates had
identical antibiotypes (E test MICs of each agent for the four isolates
were
2 gradient discrepancies): MICs of >256 µg/ml for cefoxitin,
cefmetazole, tobramycin, minocycline, and erythromycin; MICs of >32
µg/ml for ampicillin-sulbactam, imipenem, ofloxacin,
ciprofloxacin, trimethoprim-sulfamethoxazole, and
rifampin; MICs of 16 to 32 µg/ml for amikacin; and MICs of 1.5 to 2 µg/ml for clarithromycin.
RAPD patterns.
Random amplified polymorphic DNA (RAPD)
patterns of these isolates were determined by means of arbitrarily
primed PCR as described in our previous report (4). A total
of six oligonucleotide primers were used: M13
(5'-TTATGTAAAACGACGGCCAGT-3'), H3 (5'-AGACGTCCAC-3'), H4 (5'-GGAAGTCGCC-3'), H9 (5'-TGTAGCTGGG-3'),
ERIC1 (5'-GTGAATCCCCAGGAGCTTACAT-3'), and ERIC2
(5'-AAGTAAGTGACTGGGGTGAGCG-3') (Operon Technologies, Inc.,
Alameda, Calif.). For comparison, one clinical isolate of M. chelonae (isolate E) was also included in this study as a control strain. The four isolates (isolates A to D) had identical RAPD patterns
(i.e., they shared every band), and these patterns were different from
that of the control strain. Figure 2
shows the RAPD patterns for three of the primers (H3, H4, and M13).

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 2.
RAPD patterns of the five isolates of M. chelonae obtained with three primers. Lanes M, molecular size
markers (1-kb ladder; Gibco BRL, Gaithersburg, Md.); lanes A to E,
patterns for isolates A to E, respectively. Molecular sizes in kilobase
pairs are indicated to the left of the gel.
|
|
The finding in this report obtained by a molecular typing method
confirms that M. chelonae caused recurrent central venous catheter-related septicemia, which further resulted in a pulmonary embolism and soft-tissue infection of the insertion site. The recurrent
nature of the infection was probably caused by the presence of this
organism in the thrombus along the vessel wall for a period of at least
3 months, although the thrombus was not removed for microbiological
study.
Though two kinds of colonial morphology of M. chelonae on
Middlebrook 7H11 agar are well known, i.e., one is round and smooth and
the other is rough and wrinkled (8), infection caused by a
single clone of this organism which simultaneously possessed these two
obviously different colonial morphotypes has not been previously
reported. The identity of RAPD patterns with six primers was clearly
demonstrated for these two morphotypes, suggesting that they belonged
to a single clone. However, we cannot explain why the rough morphotype
was not seen in the first two positive cultures.
M. chelonae is resistant to numerous antimicrobial agents,
showing variable susceptibilities to amikacin, tobramycin, doxycycline, erythromycin, cephalosporins, imipenem, and quinolones (1, 10, 13,
14). Clarithromycin is the most active drug against this
organism, with 100% of isolates being susceptible at an MIC of
1
µg/ml (1). In contrast, our isolates were not susceptible to any of the antibiotics tested, including clarithromycin. However, after the removal of the infected catheter, our patient responded satisfactorily to treatment with clarithromycin, ciprofloxacin, and
amikacin for 1 month, followed by 2 months of treatment with clarithromycin and ciprofloxacin. Combination therapy for infections due to this multidrug-resistant organism seems advisable, although some
of the agents described had poor in vitro activity.
The findings in this case illustrate that M. chelonae should
be included in the differential diagnosis of central venous
catheter-related sepsis, particularly for immunocompromised hosts. And
this organism has the propensity to adhere to the vascular wall. When
recurrent infections occur at different sites of Port-A-Cath
implantation, clinicians should make an effort to find any vascular
lesions along the route of the catheter.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Laboratory Medicine, National Taiwan University Hospital, No. 7, Chung-Shan Rd., Taipei, Taiwan. Phone: 886-2-3562150. Fax:
886-2-3224263. E-mail: luhkt{at}ha.mc.ntu.edu.tw.
 |
REFERENCES |
| 1.
|
Brown, B. A.,
R. J. Wallace, Jr.,
G. O. Onyi,
V. De Rosas, and R. J. Wallace, III.
1992.
Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.
Antimicrob. Agents Chemother.
36:180-184[Abstract/Free Full Text].
|
| 2.
|
Cooper, J. F.,
M. J. Lichtenstein,
B. S. Graham, and W. Schaffner.
1989.
Mycobacterium chelonae: a cause of nodular skin lesions with a proclivity for renal transplant recipients.
Am. J. Med.
86:173-177[Medline].
|
| 3.
|
Galil, K.,
R. Thurer,
K. Glatter, and T. Barlam.
1996.
Disseminated Mycobacterium chelonae infection resulting in endocarditis.
Clin. Infect. Dis.
23:1322-1323[Medline].
|
| 4.
|
Hsueh, P. R.,
L. J. Teng,
S. W. Ho,
W. C. Hsieh, and K. T. Luh.
1996.
Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices.
J. Clin. Microbiol.
34:1908-1913[Abstract].
|
| 5.
|
Ingram, C. W.,
D. C. Tanner,
D. T. Durack,
G. W. Kernodle, Jr., and G. R. Corey.
1993.
Disseminated infection with rapidly growing mycobacteria.
Clin. Infect. Dis.
16:463-471[Medline].
|
| 6.
|
Koonz, F. P.,
M. E. Erwin,
M. S. Barrett, and R. N. Jones.
1994.
Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
Diagn. Microbiol. Infect. Dis.
19:183-186[Medline].
|
| 7.
|
Lowry, P. W.,
C. M. Beck-Sague,
L. A. Bland,
S. M. Aguero,
M. J. Arduino,
A. N. Minuth,
R. A. Murray,
J. M. Swenson, and W. R. Jarvis.
1990.
Mycobacterium chelonae infection among patients receiving high-flux dialysis treatment at a clinic in California.
J. Infect. Dis.
161:85-90[Medline].
|
| 8.
|
Notle, F. S., and B. Metchock.
1995.
Mycobacterium, p. 400-437.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C.
|
| 9.
|
Sran, P. K.,
K. Kansupada, and S. M. Whitcup.
1996.
Mycobacterium chelonae infection mimicking cutaneous vasculitis: case report.
Clin. Infect. Dis.
23:1189-1191[Medline].
|
| 10.
|
Swenson, J. M.,
R. J. Wallace, Jr.,
V. A. Silcox, and C. Thornsberry.
1985.
Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
Antimicrob. Agents Chemother.
28:807-811[Abstract/Free Full Text].
|
| 11.
|
Teng, L. J.,
S. J. Liaw,
P. R. Hsueh,
J. H. Fan,
K. T. Luh, and S. W. Ho.
1997.
Constitutive fatty acid and enzyme profiles of Mycobacterium species.
J. Formos. Med. Assoc.
96:336-345[Medline].
|
| 12.
|
Wallace, R. J., Jr.,
J. M. Swenson,
V. A. Silcox,
R. C. Good,
J. A. Tschen, and M. S. Stone.
1983.
Spectrum of disease due to rapidly growing mycobacteria.
Rev. Infect. Dis.
5:657-679[Medline].
|
| 13.
|
Wallace, R. J., Jr.,
J. M. Swenson,
V. A. Silcox, and M. G. Bullen.
1985.
Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonae on the basis of in vitro susceptibilities.
J. Infect. Dis.
152:500-514[Medline].
|
| 14.
|
Wallace, R. J., Jr.,
B. A. Brown, and G. Onyi.
1991.
Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.
Antimicrob. Agents Chemother.
35:773-775[Abstract/Free Full Text].
|
| 15.
|
Wallace, R. J., Jr.,
B. A. Brown, and G. Onyi.
1992.
Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.
J. Infect. Dis.
166:405-412[Medline].
|
| 16.
|
Wallace, R. J., Jr.,
V. A. Silcox,
M. Tsukamura,
B. A. Brown,
J. O. Kilburn,
W. R. Butler, and G. Onyi.
1993.
Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.
J. Clin. Microbiol.
31:3231-3239[Abstract/Free Full Text].
|
| 17.
|
Wang, H. C.,
Y. S. Liaw,
P. C. Yang,
S. H. Kuo, and K. T. Luh.
1995.
A pseudoepidemic of Mycobacterium chelonae infection caused by contamination of a fibreoptic bronchoscope suction channel.
Eur. Respir. J.
8:1259-1262[Abstract].
|
| 18.
|
Zhang, Y.,
M. Rajagopalan,
B. A. Brown, and R. J. Wallace, Jr.
1997.
Randomly amplified polymorphic DNA PCR for comparison of Mycobacterium abscessus strains from nosocomial outbreaks.
J. Clin. Microbiol.
35:3132-3139[Abstract].
|
Journal of Clinical Microbiology, May 1998, p. 1422-1424, Vol. 36, No. 5
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yang, S.-C., Hsueh, P.-R., Lai, H.-C., Teng, L.-J., Huang, L.-M., Chen, J.-M., Wang, S.-K., Shie, D.-C., Ho, S.-W., Luh, K.-T.
(2003). High Prevalence of Antimicrobial Resistance in Rapidly Growing Mycobacteria in Taiwan. Antimicrob. Agents Chemother.
47: 1958-1962
[Abstract]
[Full Text]
-
Sanguinetti, M., Ardito, F., Fiscarelli, E., La Sorda, M., D'Argenio, P., Ricciotti, G., Fadda, G.
(2001). Fatal Pulmonary Infection Due to Multidrug-Resistant Mycobacterium abscessus in a Patient with Cystic Fibrosis. J. Clin. Microbiol.
39: 816-819
[Abstract]
[Full Text]
-
Wallace, R. J. Jr., Brown;, B. A., Hsueh, P.-R., Luh, K.-T.
(1998). Catheter Sepsis Due to Mycobacterium chelonae. J. Clin. Microbiol.
36: 3444-3445
[Full Text]